Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Vitrolife, Audiocast, Q2'25

By Inderes7/17/2025, 8:00 AM
Vitrolife

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Bronwyn Brophy O'Connor
00:02 - 04:29

Good morning everyone. I would like to welcome you to the Vitrolife AB Q2 2025 Earnings Report. As mentioned, my name is Bronwyn Brophy O'Connor. I'm the CEO of Vitrolife AB and I'm joined by Helena Wennerström, our acting CFO. I would like to now move you to the slide entitled Q2 2025 highlights. I would like to start by highlighting three key achievements during the quarter. The first highlight was the performance of our consumables business, delivering 9% organic growth in local currencies excluding discontinued business. This growth rate is significantly above current market growth rates in the quarter, and there is no doubt that we are taking share from the competition across the portfolio. The second point I would like to highlight is the performance of our Americas region, delivering 5% organic growth in local currency. This is despite the fact that market conditions were very challenging in the quarter due to a significant drop in cycle numbers in the US following the signing of the IVF Executive Order on the 18th of February 2025. And the final highlight I would like to share is that we became the lead investor in Auto IVF, another key milestone as we advance our strategy of creating an end-to-end IVF platform for clinics. We will now move to the next slide, please. In addition to navigating an accelerating currency headwind in the quarter and the evolving tariff situation, this was a challenging quarter for the reproductive health industry as a whole. Following the signing of the IVF executive order in the United States, we witnessed a significant drop in cycles compared to quarter one and the same quarter last year as patients postponed their IVF treatment in anticipation of greater financial support. To date, we have no further details on what this support will entail. In Asia, we saw some small signs of recovery in China, but cycles have not returned to pre-pandemic levels. We see stronger recovery in Southeast Asia. EMEA is performing well despite the impact of the situation in the Middle East. So taking you through the numbers. Sales in the quarter were 871 million SEK, down by 7% in SEK, impacted by an 8% decline due to currency. Our CFO, Helena Wennerström, will take you through the currency impact on the financials of our company in the next slide. We delivered an organic growth of 3% in local currencies, excluding discontinued business. Despite the wider macro and industry-specific challenges that I have just mentioned. Gross margin decreased to 58%. Also impacted by currency, EBITDA decreased to 243 million SEK, resulting in an EBITDA margin of 27.8%. The margin was heavily impacted by currency, and also the increased investment in sales and marketing in the US played a role. Operating cash flow was 151 million SEK, and earnings per share were 0.74. If we then take a look at the first half year of 2025, sales were 1.7 billion SEK. That's minus 4% in SEK, impacted by -4% due to currency. Organic growth was plus 3% in local currencies, excluding discontinued business. Year to date EBITDA. As you can see there on the slide, 500 million SEK and operating cash flow 220 million SEK. I'm now going to hand you over to Helena, who will take you through the specifics of the currency impact on the Vitrolife AB group. Over to you, Helena.

Helena Wennerström
04:30 - 07:25

Thank you. Bronwyn. We are now on page number five, where I will provide a more detailed analysis of the currency situation in the first half of 2025, as developments accelerated significantly in Q2 2025. First, some words about what is reflected in translation and in transaction effects. Translation effects arise from the net investments in foreign subsidiaries. Revaluation impacts the equity assets and liabilities translated at the closing date rate. Revaluation impacts other operating items. Transaction effects attributable to income and expenses are converted at the average rate for the period. However, transactions in foreign currency are measured in the functional currency at the exchange rate that applies on the transaction date. Now over to the impact that has been observed in the results for the period in Q1. If I could draw your attention to the arrow on the right-hand side, we can clearly see a significant strength in the Swedish crown versus other currencies by the end of the quarter, which impacted the result with a translation effect of -13 million SEK, but no major transaction effects in the period. In Q2, the Swedish crown currency has been less volatile, and we can see less impact of translation. Effect in the operating expenses amounted to -5 million for the quarter. Year to date, 2025 totals to -77 million, representing approximately -4% for the period. Notably, only -4 million SEK of this impact relates to the transaction effects from Q1 2025. A large part of the transaction effect was visible already in the gross result, but when it comes to operating costs, there is a counteracting effect of foreign costs and their currency impact. But still, we have a large part of the operating cost in Swedish Crown as a reference in 2024. We are short in Danish crowns and Swedish crowns, long in all other currencies, as shown in the Annual and Sustainability Report for 2024. And with that, I will hand over to you, Bronwyn, again.

Bronwyn Brophy O'Connor
07:25 - 13:44

Thank you. Helena. We can now move to the next slide titled Sales and Growth for Geographical Segment. Sales in the Americas region increased by 5%. Despite the very challenging IVF climate in the United States. After the IVF executive order that I previously mentioned, the growth we delivered was primarily driven by market share gains in genetic services in North America. The comparables in technologies were exceptionally challenging as we grew 174% in technologies in Q2 2024 due to closing a large EmbryoScope deal with the clinic chain. Even with these very high comparable technologies, the Americas were only -1% behind the previous year. A strong performance in our largest region, EMEA, driven by, it must be said, an exceptional performance in our consumables business across the region, delivering 17% growth in local currencies, excluding discontinued business. We most definitely took share from competitors in several categories. This region also had substantial comparable challenges in technologies, as we grew by more than 50% in Q2 of 2024. Although we saw a more robust recovery in Southeast Asia, the overall cost of raising a child in APAC appears to be impacting cycle numbers in the wider region. And if I can draw your attention then to the share of total sales, you can see that EMEA continues to be our largest region with 33% share of total sales, followed by Americas with 34%. Even with these very high comps technologies, the Americas were only -1% behind the previous year. I'll now move on and we'll take a deeper look at market region EMEA. So as I said, a strong performance by our largest region driven by Europe. A Vitrolife AB Group stronghold. It has to be said, we continue to expand our market leadership position in several key markets and parts of the portfolio in the region. Our total growth was -8%, impacted by -5% due to currency effects and -8% due to discontinued business in the quarter. To repeat, our organic growth in local currency, excluding discontinued business, was plus 5%. Sales in consumables were up 17% in local currencies, excluding discontinued business. And I want to thank the team for the fantastic job that they did, taking share across the portfolio in all markets. Sales in genetics in this region were impacted by the situation in the Middle East. Um, but we did see steady growth across the portfolio in other markets, which was encouraging to see. And then a tough quarter here for technologies in the region, as I previously mentioned. However, what is very encouraging to see here is that the revenue per installed EmbryoScope is increasing steadily. Even with these very high comps in technologies, the Americas were only 1% behind the previous year. We will now move to Market Region. Americas. So tough market conditions. As I mentioned in parts of the Americas region, this is a result of the IVF executive order, which started to impact cycle levels as we moved into Q2. In the Vitrolife Group, we conducted a patient survey across the high-volume IVF states in America, and it confirmed that couples were delaying their IVF treatment while awaiting clarity on financial support. The statement from the White House. Just for those of you who haven't had a chance to read it, the statement from the White House, and I will quote, was to aggressively reduce out-of-pocket costs for IVF. Clearly, when this materializes, this will be good for patients, but we are still in a holding pattern awaiting further news from the US administration. Total growth was -6%, impacted by an -11% currency factor here. So, we achieved an organic growth in local currencies of plus 5%. As I mentioned before, there was an exceptionally strong comparable quarter last year for technologies due to a large purchase from one of the biggest cross-border clinic chains, in fact. Um, but what I would say is that despite the drop in cycles and the very strong comps in technologies, we still managed to deliver growth. And this is due to share gains in our genetic services business, which is performing very strongly this year across the entire portfolio. So, there are strong share gains and momentum in genetic services. Okay. I'd now like to move on and take a deeper look at the market region. APAC market conditions in APAC are quite mixed from one market to another. Cycles have not returned to pre-pandemic levels in China, and Australasia is flat and even negative in certain parts. But South East Asia is showing good signs of recovery. What we are seeing across the region is the delaying of capital purchases, as chains and individual clinics manage their cash. So a flat organic growth in local currencies, negative growth in technologies despite a healthy sales funnel of EmbryoScope because we are impacted by these delayed capital purchases, especially in the larger markets. And in fact, consumables performed well in all markets, even those impacted by lower cycle growth rates. So with that, I will hand you back over to Helena, who will take us through the geographical segments.

Helena Wennerström
13:46 - 24:41

Thank you, Bronwyn. We are now on page number ten, where I will provide a more detailed analysis of the geographical segments Americas, EMEA, and APAC. Starting on the right-hand side. As mentioned earlier, total sales amounted to 871 million, with a gross margin of 58% in comparison with the previous year. Sales were 941 million, with a gross margin of 59.9%. The market contribution was 302 million, with a contribution margin of 34.7%. In the same quarter last year, it was 369 million, with a contribution margin of 39.2%, a decrease of 4.5 percentage points, primarily driven by currency fluctuation changes and slightly increased supply chain costs. Let us now take a closer look at the geographic segments. On the left-hand side in the Americas, sales totaled 295 million, reflecting a 5% organic growth in local currencies. But the decline of 6% in constant currency (CC) was negatively impacted by currency effects of -11%. As mentioned earlier, we had solid growth despite the significant drop in cycles following the US IVF executive order. Gross income totaled 160 million, with a gross margin of 54.2%. This compares to last year's gross income of 181 million and a margin of 57.3%, a decline primarily driven by currency fluctuations. However, there was an improvement of 0.5 percentage points compared to the previous quarter. Selling expenses for the quarter rose from 63 million to 75 million, reflecting ongoing investments in sales and marketing in the US. As previously announced, the market contribution margin for the quarter was 29%, representing an improvement of 3.7 percentage points compared to the previous quarter. Sales in EMEA declined by 3% in local currencies and by 8% in SEK, totaling 326 million SEK. The sales were negatively impacted by a currency effect of -5%. Excluding discontinued business, sales increased by 5% in local currencies. Gross income was 195 million, with a gross margin of 59.9%, compared to 250 million and a margin of 60.5% last year. The decrease was mainly due to currency effects and product mix. Selling expenses decreased from 90 million to 81 million. The market contribution margin for the quarter was 35%, slightly down from 31.5%, affected by currency fluctuations, product mix, and lower selling expenses in APAC. Among the sales, which amounted to 250 million, reflecting flat organic growth in local currencies, but an 8% decrease in SEK, primarily due to a -7% currency impact. Gross income was 150 million with a gross margin of 59.8%, which is lower than the previous year's gross income of 169 million and a gross margin of 61.6%. Percent. However, there was an improvement of 1.5 percentage points compared to the previous quarter. Selling expenses increased from 42 million to 47 million, and the market contribution margin for the quarter was 41%, down from 46.7% last year. Let's move on to slide number 11. On this slide, I will comment on Q2 financial highlights. As earlier mentioned, the sales amounted to 871 million compared to the previous year, with sales of 941 million, corresponding to a flat growth in local currencies. A 7% decrease in SEK and 3% in local currencies, excluding discontinued business. As part of our ongoing risk assessment procedure and to ensure we continue to comply with all applicable international sanctions, we decided to discontinue activities in certain markets in EMEA, as we announced in the Q4 2024 report, representing less than 3% of our annual revenue. Effect. From 1st of January 2025, the gross income amounted to 505 million, compared to 564 million the previous year, corresponding to a gross margin of 58%, down from 59.9% the previous year, negatively impacted by currency fluctuations and a slightly increased supply chain. In the second quarter, operating expenses increased, primarily attributable to the previously communicated investment in expanding sales and marketing capabilities in the US, as well as increased administrative expenses driven by ongoing activities within the company, and part of it is to be considered as one-off costs. Operating expenses were also impacted by a negative effect when regulating assets and liabilities at the closing rate. By the end of the quarter. All in all, this gives us an EBITDA of 243 million compared to 327 million the previous year, resulting in an EBITDA margin of 27.8% compared to 34.7% last year. The decrease in margin is heavily impacted by transaction and translation effects, driven by a strengthened SEK against other currencies. Furthermore, the margin was also affected by increased selling expenses, mainly in the US, combined with the impact of product and market mix. Let's move on to slide number 12. Some comments about our operating expenses. As previously communicated, we continue to invest in sales and marketing capabilities in key markets, resulting in an increase in selling expenses from 196 million to 203 million. R&D expenses have risen slightly year over year by 2 million SEK. Administrative expenses are higher and related to ongoing activities within the company and part of it is to be considered as one-off costs. Other operating expenses remained flat at 2 to 6 million SEK compared to the same quarter last year. However, the operating expenses are mainly affected by translation effects, amounting to -5 million in the quarter versus -3 million in the comparable quarter, related to the revaluation of assets and liabilities at the closing rate. Let's move on to slide number 13. Let us now look at some key financials. Here I will focus on the year-to-date numbers. And sales for the first half year amounted to 1.7 billion, corresponding to flat growth in local currencies, a decrease of 4% in SEK, and a 3% decrease in local currencies, excluding discontinued business. The gross margins decreased from 58.6% to 57.7%, and the EBITDA amounted to 500 million, compared to 600 million, corresponding to an EBITDA margin of 29.2% versus 33.6% this year. The decrease in the margin is heavily impacted by transaction and translation currency effects, driven by the strengthened SEK against other currencies, but the margin was also affected by increased selling expenses, mainly in the US and the product and market mix. The financial net amounted to -15 million compared to -48 million in the previous year, primarily positively impacted by a foreign exchange gain of 8 million compared to -4 million in the previous year. Interest expenses amounted to 31 million, compared to 48 million in the previous year. Net income amounted to 198 million, compared to 258 million the previous year, heavily impacted by currency fluctuations, which gives earnings per share of 0.74 Swedish crown compared to 1.06 Swedish crown the previous year. Taxes amounted to -73 million, compared to -77 million the previous year, and the effective tax rate was 6.9% for the first half of the year, compared to 23% for the same period the previous year. The increase this year is driven by restructuring activities, withholding taxes, and geographical market mix. Main part. Effective in Q1 2025. Historically, the normalized average tax rate amounted to approximately 23 to 25%, depending on the geographical market mix. Operating cash flow amounted to 220 million for the first half of the year. For the first half of the year, compared to 434 million the previous year. Changes in the working capital had a negative effect of 134 million this year, compared to 62 million the previous year, affecting all working capital items. The taxpayer, with a year-over-year increase of 81 million SEK, is a timing matter, and we have a strong balance sheet with an equity ratio of 78.8% and a net debt to EBITDA of 0.8, compared to 1.0 previous year. By the end of the quarter and additionally at the beginning of July. We also have signed a €300 million loan agreement consisting of a term loan to refinance the existing debt and a revolving facility for general corporate purposes. And I will now hand over to you again.

Bronwyn Brophy O'Connor
24:42 - 27:13

Thank you. Helena. So the focus for the rest of the year is, well, growth. Number one is to continue to drive share gain in key markets by leveraging the full breadth of the portfolio. I think, particularly on the consumable side, we've been doing this really well for several quarters now. Um, the second imperative is to accelerate penetration of our combined EmbryoScope and lab-controlled solutions. And then it's very important to deliver best-in-class quality and customer service, both of which are synonymous with our company and help to differentiate us from our competitors. In relation to innovation, we have prioritized those programs that deliver solutions to help clinics automate, scale, and improve outcomes. So essentially, what we're doing is prioritizing the platform-related R&D programs. Um, and we've also strengthened our market access capabilities, particularly to assist us with some of the US approvals related to operational excellence. I guess the key point I would like to highlight here is automating our manufacturing to increase the capacity of key growth drivers. This has been really critical to meet the demand forecasts, particularly in our consumables business, where we have been gaining share for several quarters across the portfolio. And then in relation to the macroeconomic environment, well, it's clearly quite volatile. Additionally, we need to stay very close to the evolving situation with tariffs in the US and the IVF executive order in the US. There's only so long that you can do this for because the window for successful IVF is very small. So I guess we will see as the months progress. Um, well, first of all, how soon can we get an update from the US administration and then for how much longer are our patients going to postpone? And then I think, very importantly as well, for our region, our largest region, which is performing very well, is to be ready to rescale activities in the Middle East in the event that certain markets reopen there. So with that, I'd like to thank you for your attention, and we'll now hand over to the moderator to open up for Q&A.

Operator
27:15 - 27:43

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. Please start by asking one question followed by a follow-up question. It's then fine to queue up again for more questions. The next question comes from Ulrich Trattner from NAB Carnegie. Please go ahead.

Ulrich Trattner
27:46 - 28:09

Thank you very much. Uh, my question would be on your impression of the underlying growth for respective markets in Q2, mainly for EMEA and the Americas and Asia, specifically for the US. And what is driving your market share gains in EMEA consumables as well as in Americas genetics?

Bronwyn Brophy O'Connor
28:13 - 28:20

Yeah, so thank you for the question, Ulrich. I think part one is, what do I think the underlying growth is in EMEA and the Americas. Um, and we've also strengthened our market access capabilities, particularly to help us with some of the US approvals in relation to operational excellence.

Unknown 1
28:20 - 28:21

Um, and we've also strengthened our market access capabilities, particularly to help us with some of the, uh, US approvals in relation to operational excellence. Yes, that's correct.

Bronwyn Brophy O'Connor
28:23 - 30:18

Yeah. So, um, cycles are down; cycles are down in the US. But of course, for us, the Americas include the US, Canada, and South America. But cycles specifically in the US are down compared to the previous quarter. So, in Q1 they were tracking healthily, I would say, and they are down versus Q1 and down versus last year. Um, it's not the cancellation of cycles per se. It's a postponement. I mean, obviously that statement came out from the White House on the 18th of February. It was a very strong statement. IVF is expensive in the US, so you can completely understand why patients would pause. So cycles are down. Um, which to me highlights that our consumables performance and our genetics performance, more specifically in North America, is very strong. That's due to share gains. We've been capturing more market share in genetic services, not so much in genomics, but specifically in genetic services in North America for several quarters now. And that really drove the growth in the Americas region. EMEA cycles are positive, so cycles are growing. Um, but they're not growing to the level of our consumables gains. And really where we're taking share is across the consumables portfolio. Ulrich. Um, as you know, we have been taking share on the media side for quite a while, but we're now taking share in other parts of the consumables portfolio. So disposable devices, pipettes, and needles are basically everywhere. I mean, to have the growth of 17% excluding discontinued business is significantly double-digit, above what the cycle growths are in the region. So hopefully I've answered your question the way you intended it.

Unknown 1
30:18 - 30:19

Yes, absolutely.

Ulrich Trattner
30:19 - 30:49

And just a follow-up question on genetics in the US. What specific tests are driving growth? And also note that you submitted the dismissal of the PPA class action suit during June. So, the first follow-up question would be, which tests are driving growth? Secondly, have you seen any material impact from this on PGT-A sales isolated to the US?

Bronwyn Brophy O'Connor
30:51 - 31:37

Yeah. So I can answer the second part first because it makes the first part easier. There's no impact because the PGT-A family of tests is what's driving the growth. It's the largest part of the revenue. And it's driving the growth. It's significant. Um, and that's, I mean, if we look at our 12-month rolling by test, obviously, we don't divulge this information. I'm sure we have plenty of competitors listening in this morning. So we don't divulge that by test. But, um, it is the largest part of the revenue in North America. Um, and it's performing. It's performing well. And it has not been impacted in any shape or form by the class actions.

Unknown 1
31:38 - 31:39

So we don't divulge that by test.

Ulrich Trattner
31:39 - 31:41

Thank you, Bronwyn. And I'll get back into the queue.

Bronwyn Brophy O'Connor
31:43 - 31:45

Sure, Varsha. Good. So we don't divulge that by test. Ulrich.

Operator
31:47 - 31:52

The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
31:54 - 32:20

Yes. Good morning. Uh, a question on the cycle growth in the U.S. during the quarter. Can you comment on whether there were any differences in growth at the start of the quarter compared to the end, and if the growth rate picked up by the end of the quarter or if it showed similar growth month over month?

Bronwyn Brophy O'Connor
32:23 - 33:19

Yeah. So, excellent question, Sten. So we don't divulge that by test. Um, um, the cycles improved slightly as the quarter advanced. So the biggest drop was at the start of the quarter. It was slightly less in April. Uh, you know, sorry. April. May, June, essentially, April was bad. May was a little bit less bad and then slightly better in June. So it would appear, um, I never like guessing when it comes to this executive order, to be honest, but it would appear, based on our data, that patients had waited the 90 days. Then, when they saw that nothing was coming out, obviously the big, beautiful bill was going through the House, and that was the focus of the administration. But I think as patients saw that there was no update coming on the IVF executive order. They slowly started to return to the clinics. Yeah.

Sten Gustafson
33:19 - 33:20

Excellent. Thank you.

Bronwyn Brophy O'Connor
33:20 - 33:23

So, the phasing was as expected, following the trends we anticipated. Yeah. You're welcome.

Sten Gustafson
33:24 - 33:59

And then if I may squeeze in, uh, some sort of a follow-up there, but sort of on the broader growth for the company, it's been relatively muted now for the first half. And what do you see near term for the coming two quarters, in terms of, do you expect growth to improve, or. Do you give any guidance? Can you give any guidance on the outlook for the second half? That would be helpful.

Unknown 2
34:01 - 34:03

Yeah. So typically.

Bronwyn Brophy O'Connor
34:03 - 36:34

We don't guide. But I'll try to give you my, my, um, based on what we see, it's quite region-specific, Stan. So, um, EMEA is looking very solid actually. Um, so that's looking good. Europe across the board is looking pretty good. And for us as a company, I don't know what it's like for our competitors, but for us as a company, we're performing well in all markets with the exception of the Middle East, which we all know. The reasons why that has been impacted. Um, Asia is very much a mixed bag. So, so, uh, cycles have not recovered in, in China. They're not; they're better than the levels at which they were in quarter one, but they have not returned to pre-pandemic levels. So, so China's looking soft. Southeast Asia is looking a lot better. Um, so a little bit of a mixed bag in APAC. And then, you know, the biggest question is obviously the Americas, because North America is the largest part of that market by quite a distance. It's the largest IVF market in the world. And it also had, in the context of being a large market, one of the healthiest growth rates globally prior to the executive order being signed. And so, the postponement or, I guess, the delay in providing clarity to couples on what that additional financial support will mean, is making it very difficult to make a call on North American growth. What we do know for sure is that this pent-up demand exists because we've been speaking to our clinics, the clinic chains, and also some of the smaller clinics. They're not seeing patients canceling cycles. They're seeing them postpone them, which is completely understandable. I mean, IVF is very expensive in the United States, and any financial assistance is going to go a long way. So, um, you know, in, in many ways in relation to the US, if we could just get clarity either way, it would be good for growth. Either financial assistance is coming, which is fantastic, or financial assistance is not coming. And we can get back to the healthy growth rates that we've had in the market for several years. So it really depends by region. Stan. Um, the sooner we get clarity in the United States, the faster we can get the growth up.

Sten Gustafson
36:34 - 36:36

Excellent. Thank you very much for your comments.

Bronwyn Brophy O'Connor
36:38 - 36:40

Yeah. You're welcome. Thank you for your questions.

Operator
36:43 - 36:47

The next question comes from Jakob Lemke from SEB. Please go ahead.

Jakob Lemke
36:52 - 37:11

Good morning. A question on technologies. Uh, so in Q2 here, uh, you talked about a slightly weaker quarter in APAC. Americas seems to be experiencing a stronger quarter. Uh, so just in general, what is your outlook and sort of how is the pipeline for technologies here in the coming quarters across the regions?

Bronwyn Brophy O'Connor
37:14 - 39:16

Yeah. So, uh, thank you for your question, Jakob. Um, so the pipeline is good. I mean, even in APAC, the pipeline is pretty good for EmbryoScope. But we are seeing that the dynamics are quite different by region, so I'm going to take you through the three regions. So, in APAC, there's a good funnel. Uh, very good funnel. Even in the markets where cycles haven't recovered to historic levels, you know. Um, but we're seeing continued delays in capital purchases. So again, it's not like the EmbryoScope orders are being canceled. It's delaying as clinic chains and individual clinics, you know, hold on to their cash in volatile times. Um, APAC is our most penetrated region for EmbryoScope. Um, but EmbryoScope has been performing well there. Um, and I guess the other thing we need to think about here, Jacob, is the consumable revenue per EmbryoScope. We don't divulge exactly what that is. Um, but it's becoming a healthier proportion. And that's trending very nicely in EMEA. Um, and then in the Americas, we've really been focusing on EmbryoScope, and we've been getting some very nice traction there. The funnel has been building, but again, there, we have a little bit of a holding pattern, less than in APAC. It has to be said. We have a little bit of a holding pattern on technologies. Um, just with the whole, uh, executive order, I guess, sort of impacting confidence a little bit. But the funnel overall for EmbryoScope is healthy. It's the timing of when the systems come in, and we do see the time to order, which we measure, is taking longer; it's increasing. But the consumables revenue per EmbryoScope across the globe is increasing nicely. So hopefully that gives you a bit of a flavor. Jacob.

Jakob Lemke
39:18 - 39:27

Yeah. And just on APAC, when do you think this sort of caution from the clinics will move away and they can start to execute their orders?

Bronwyn Brophy O'Connor
39:30 - 40:37

Yeah. Uh, it depends on the markets in, in APAC. So, um, I mean, you know, if we if we just take China as an example, as I mentioned, cycles haven't returned to sort of historic or pre-pandemic levels. Um, and, and I guess the clinics in general would like to see some green shoots. We have seen some green shoots. Nothing to get too excited about. Um, but I guess the clinics are waiting for a little bit more confidence in the cycle side. I mean, reimbursement has improved. It hasn't had an impact yet. You know, our government's going to become more aggressive on the reimbursement side. We look at what's happened in South Korea. The government's gone very aggressive on financial support. And it has helped, you know, countries like China and Japan are likely going to have to do the same if they really want to move the needle. So all of that sort of helps confidence in investing in an EmbryoScope. Um, and then Jacob, was there a second part to your second question that I missed or have I clarified?

Jakob Lemke
40:38 - 41:00

No, you can clarify. Maybe if I can just shoot in a more general question before getting back in line. Um, so, you know, I guess 2025 has been a sort of tougher year for many of your key markets. But when you now look into 2026, what are you seeing there? And also do you think it's possible to get back to your growth target of 10% next year?

Bronwyn Brophy O'Connor
41:03 - 42:32

Yeah. So again, it comes back to the three-part story. We think Amaya is good and steady, particularly in Europe. Europe is better than good and steady. That's for the Vitrolife AB group. We're doing very well in, in EMEA. Um, if financial support comes in the US, then we will see an uptick in cycles. Um, that would be expected. It won't be explosive because the capacity is not in the system right now. It would take time for that to filter through. Um, but you know, any financial support in the US will help the Americas region. I guess where I would be more cautious is on APAC, um, because we do have several large markets there. When I say large, I mean large in absolute numbers of IVF cycles. And we see that, you know, despite improved reimbursement, the cycles quarter over quarter, there can be fluctuations in performance. But if you look at the rolling 12 or 24 month cycles, it's not very exciting. So APAC seems to have more endemic challenges, one of which is the overall cost of raising a child. And I think that's why you're starting to see some of the governments step in. So I think, you know, again, a steadier, more optimistic outlook for the Americas, but a more conservative outlook for APAC.

Jakob Lemke
42:34 - 42:36

Okay. You're welcome. I'll get back in line.

Bronwyn Brophy O'Connor
42:38 - 42:39

You're welcome. Thank you. Jacob.

Operator
42:42 - 42:46

The next question comes from Johan Honoris from Redeye. Please go ahead.

Johan Honoris
42:48 - 43:19

Great. Thank you for taking our questions. The first one, I can follow up on the US side. Clearly, the consumers or clients are hesitant and postponing. Is there an element of uncertainty in the administration budget also affecting clinics in terms of activity and perhaps encouraging patients to go further? Is that administration budget uncertainty also affecting clinics in terms of activity and perhaps encouraging patients to go further?

Bronwyn Brophy O'Connor
43:23 - 43:32

I'm sorry, Johan, I'm struggling to hear you a little bit. So I think your question isn't clear, maybe could you repeat the question?

Unknown 3
43:33 - 43:33

Yeah.

Bronwyn Brophy O'Connor
43:33 - 43:34

No, if you could.

Johan Honoris
43:36 - 43:46

Let's see. I can change, uh, perhaps go directly. Maybe my iPhone was acting up. Yeah. Is that better?

Unknown 4
43:46 - 43:47

That's great.

Unknown 3
43:47 - 43:48

Great.

Unknown 2
43:48 - 43:49

That's much better.

Unknown 3
43:49 - 43:49

Thank you.

Johan Honoris
43:49 - 44:28

I just go, um. Sorry for the confusion. Now it's sealed so it doesn't pop open automatically. Yeah. No, your message regarding us in terms of patient behavior is pretty clear. It seems that many patients are postponing and not canceling. But what about the changes, of course, in budgets and administration? Is that having an impact perhaps in how the centers are incentivizing their patients to go further? There could be an element of that as well, I suspect.

Unknown 2
44:29 - 44:29

Yeah.

Bronwyn Brophy O'Connor
44:29 - 45:42

We're not the industry. Not Vitrolife AB Group. So reproductive health as a whole isn't heavily impacted by some of the central government cuts or cuts to things like NIH funding. I mean, we're not completely immune to it, but, you know, I mean, most of the clinics in the United States are part of a chain—60%—and most of those chains are privately owned. And there are some, for sure, certain clinics that are linked to academic centers. There are some clinics that are linked to academic centers, you know, the Columbias and Cornells of this world. But so far, the sort of funding on that reproductive health side hasn't been impacted. I mean, the administration has been pretty clear, not just President Trump, but the wider administration has been very clear that they want Americans having more babies. Um, and they're very supportive of providing support for couples to do that or for individuals to do that. Um, so, so we haven't really, you know, to date, I couldn't say we've been impacted by that in any material way. Yeah.

Johan Honoris
45:43 - 45:46

Great. Ah, a similar question related to.

Unknown 4
45:46 - 45:46

Yeah.

Johan Honoris
45:47 - 45:48

Then, um.

Unknown 5
45:48 - 45:49

Go ahead.

Johan Honoris
45:49 - 45:50

Sorry.

Unknown 5
45:50 - 45:51

No, I was.

Johan Honoris
45:51 - 45:51

Going.

Unknown 3
45:52 - 45:54

I was going to say healthcare, which would.

Bronwyn Brophy O'Connor
45:54 - 45:59

Be significantly impacted, but not really our space. Yeah.

Johan Honoris
46:00 - 46:34

Yeah. And in the APAC region, the more regional approach doesn't seem to work very well, or at least it's causing friction, to put it mildly. Um, at the same time, the reimbursement seems to be improving. What should we expect here? Should we expect more reimbursement to try to kickstart the market from a central perspective? Uh, or should we expect the regional approach to start being backtracked to some extent?

Bronwyn Brophy O'Connor
46:35 - 48:15

Yeah. Um. Difficult to predict, but I think the green shoots that we're seeing in countries like Korea, where the decline has halted from a very low base, it has to be said. But I think that's going to become a proxy for how aggressive governments are going to go. And what I would say is that what we're hearing much more of in APAC is not just IVF reimbursement and coverage but improved support for the cost of raising a child. So things like tax breaks or payments for having children. So I think where we're going to see more support is on the additional costs of raising a child, as well as reimbursement costs for IVF. You know, are they going to do this? Are they not? I don't think they're going to have any choice. If you look at the declining birth rates, I mean, this is only going in one direction. So the biggest factor here is people are having fewer children. They're delaying having the children that they do have, which means inevitably a lot of them are going to need IVF support. Um, and, and population decline is very stark globally now. There was a recent UN report published in April. So governments will have no choice but to step in. I don't see them standing by and watching their populations fall off a cliff. So, um, APAC in general, Asia in general is going to have to get more aggressive on helping couples in the case of APAC to have a child, and to support child-raising costs.

Johan Honoris
48:17 - 48:30

Yeah, that of course sounds very realistic and likely, but indirect incentives and support may, of course, take some time to gain traction and go through Parliament and the likes.

Bronwyn Brophy O'Connor
48:31 - 48:38

Yeah, exactly. No, I think you're right. I think in the shorter term that's going to take time for sure. Yeah.

Johan Honoris
48:39 - 48:41

Yeah. Thank you.

Unknown 3
48:43 - 48:43

You're welcome.

Operator
48:47 - 48:51

The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Johan Honoris
48:54 - 48:54

Yes. Hi.

Ludvig Lundgren
48:55 - 49:13

Um, so I have two questions regarding costs. So opex to sales was 42% here in Q2, the highest level in quite a while for Vitrolife AB. And I wonder if there were any sort of one-off costs in the quarter and how we should think about opex sales moving into H2.

Unknown 4
49:16 - 49:17

Yeah. Helena.

Helena Wennerström
49:17 - 49:37

Yeah. Uh, as we said earlier, there are ongoing activities within the company that have actually increased the cost for this quarter. And part of it is considered to be one-off costs. Some of it will continue, but part of it will be one-off for this quarter.

Ludvig Lundgren
49:41 - 49:56

Thank you. Thank you. Um, and then on the FX side, I suppose that has also affected margins quite a bit here in Q2. So I wonder if you could share the organic opex growth for the group in Q2.

Helena Wennerström
49:58 - 50:16

Uh, as I said earlier, it has offset a little bit of the costs. But the major part is on the gross income side. So, we still have quite a major part of our opex in Swedish kroner.

Ludvig Lundgren
50:19 - 50:20

Okay. Thank you.

Bronwyn Brophy O'Connor
50:24 - 50:24

Thank you. Ludvig.

Helena Wennerström
50:25 - 50:25

Thank you.

Operator
50:28 - 50:33

The next question comes from Susannah Warner from CHB. Please go ahead.

Susannah Warner
50:36 - 51:19

Hello and thank you for taking my question. I just wanted to follow up on the question. Regarding the margin declines that we saw in the Q2 report, should we think of that as a one-off, or is it fair to continue assuming the financial targets in terms of the EBITDA? And then as a follow-up question, I wanted to just sort of get a better grasp of Japan because historically, their contribution in APAC, and specifically the benefits you've seen in sales as a consequence of reimbursement, have been significant. So maybe you can give us a little bit of granularity on that. Thank you.

Unknown 3
51:22 - 51:22

Yeah.

Bronwyn Brophy O'Connor
51:22 - 51:29

So I'll hand over to Helena to take your first question, and I'll take your Japan one, if that's okay. Susanna, thank you for your questions.

Helena Wennerström
51:30 - 52:08

Thank you, Susanna. So the margin, it is partly due to the currency effects, as we have already mentioned. But also, some of it is now coming into play; it's not a major cost, but it has come into our supply chain costs during Q2. So, as you know, that is still on the table going forward as well. And then we also have some minor effects from product mix and one-offs affecting the margin. I just wanted to follow up on the question.

Bronwyn Brophy O'Connor
52:09 - 53:48

Yeah. Japan. Susanna, that is an interesting one. Um, and it's nice to get a question about Japan. So, Japan is a very large IVF market with a really good or comparatively good reimbursement system. Um, and the reimbursement system has been gradually improving and includes things like broader genetic testing. Um, so what we see in Japan is, we see some signs of pick up on the consumable side of the portfolio, which is good. What I can't give you is a breakdown of how much of that is coming from cycle growth and how much of it is coming from share gain. But we estimate internally that our Japan consumable growth is mainly coming from share gain. Um, but it's good to see it. Um, what I would say is Japan is also impacted by the delay in capital purchases. So that's not just it; it's across APAC, even in the markets that are showing some green shoots like South Korea and Japan. Um, but it's, you know, you're correct. It's a sizable market. It has good reimbursement. Um, I think in fairness to the Ministry of Health in Japan, they are increasingly trying to find ways to support couples on the reimbursement and on the financial side. And maybe some of those green shoots are starting to come through. Currently. So hopefully that answers your question, Susanna.

Susannah Warner
53:50 - 53:51

Yes. Thank you.

Bronwyn Brophy O'Connor
53:52 - 53:53

Welcome.

Operator
53:56 - 54:00

Next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Ulrich Trattner
54:03 - 54:30

Thank you very much for taking some additional questions. And also on the OpEx side. Um, I understand the rationale behind you. You're increasing your selling expenses, especially in the Americas. However, administrative expenses have increased by more than 10% year over year, and you mention ongoing activities. What are these ongoing activities? And I think you mentioned that there would be some one-offs in these. If you can explain what these one-offs are, that would be very helpful.

Helena Wennerström
54:34 - 54:57

And the kind of one-off cost is mainly due to our work with legal support here related to the class action lawsuit in the US, as well as some costs related to other insurances connected to this in the US.

Unknown 1
55:01 - 55:01

And maybe some of those green shoots are starting to come through.

Ulrich Trattner
55:01 - 55:06

And what are the ongoing activities then that would sort of make up the rest of this?

Helena Wennerström
55:08 - 55:21

Yes, I would say that it is. The major part of it is really one-offs in the quarter. But some of it will continue, and that is the balance.

Ulrich Trattner
55:21 - 55:34

And maybe some of those green shoots are starting to come through. But we should see these ongoing activities and one-offs as being mostly related to the class action lawsuit in the US on different cost areas.

Bronwyn Brophy O'Connor
55:36 - 56:38

Yeah. What I would say, Ulrich, is sorry Helena, to jump in on your turf, but we've been very tightly controlling everything from headcount and T&E costs, and obviously that's the responsible thing to do. So it's not a sort of blow up in any areas. But, you know, a couple of small items. I think Helena is correct. Um, it's not the majority, but a significant proportion of it in this quarter comes from defense costs for the legal action, which you can see is starting to advance slowly, and then insurance costs related to the class action, so that's maybe not the majority of it, but a significant proportion of that. Some of that is one-off. Um, not all of it, but some of it is one-off cost. So for example, a specific legal defense is going to be a one-off, while insurance tends to be a little bit longer term. So hopefully that's a little bit more clarity for you on that one. Yeah.

Ulrich Trattner
56:38 - 56:40

I completely agree.

Unknown 3
56:40 - 56:40

Yeah.

Bronwyn Brophy O'Connor
56:40 - 56:50

But it's not like we have any particular line that's sort of blowing up. We've been in tightly on top of it. Yeah. We've been very much on top of the cost. So yeah.

Ulrich Trattner
56:52 - 57:20

No, that's great. Thanks for that granularity and an additional question on my end, and I'll get back. Uh, it's on the discontinued markets. Uh, if there is any. Do you estimate any sort of dramatic changes in H2 versus H1 in terms of those markets' contribution to both top line and bottom line? Um, or just kind of the same.

Unknown 5
57:22 - 57:24

Yeah. So, the biggest.

Bronwyn Brophy O'Connor
57:24 - 58:02

The impact from the discontinued business was in this quarter, and this was actually the biggest one in EMEA. Um, then we get more back into the range that Helena talked about, which was 3.2%. Um, so it doesn't get lumpier. Uh, Ulrich mentioned that, yeah, this was the biggest one. This was the strongest quarter in that market, in 2024. So it gave an additional headwind this quarter. Yeah.

Ulrich Trattner
58:04 - 58:04

Perfect.

Unknown 3
58:04 - 58:05

And thank you.

Ulrich Trattner
58:05 - 58:05

You.

Unknown 3
58:05 - 58:06

Very much.

Bronwyn Brophy O'Connor
58:07 - 58:25

Maybe your backup question, because I know how you think. Well, I know partially how you think. Uh, you know, do we see additional activity in countries close to that discontinued market? No, we don't see that. Um, so. Yeah.

Ulrich Trattner
58:26 - 58:52

Very much. That's great. And the same on profitability as well. Not on the top line, I guess. Sorry. Did you catch my last follow-up there?

Helena Wennerström
58:52 - 58:55

No, I think we were disconnected. So, please.

Bronwyn Brophy O'Connor
58:55 - 58:56

Did you have another question?

Ulrich Trattner
58:56 - 58:58

Very much. Sorry. No, it was.

Unknown 3
58:58 - 58:59

Just a clarification.

Ulrich Trattner
58:59 - 59:08

That it was. It was not. Yes, absolutely. Yeah. Sorry. It was just a clarification that it was not only on the strongest on, on top line, but also on bottom line.

Unknown 3
59:09 - 59:10

Yeah.

Ulrich Trattner
59:10 - 59:11

Discontinuing markets.

Unknown 3
59:11 - 59:11

Yeah.

Bronwyn Brophy O'Connor
59:11 - 59:31

Exactly. So, this quarter was strong on both the top and bottom lines. And it starts to moderate. Yes. And it gets to more normalized, discontinued levels in Q3. And for this, this was the quarter where it had the greatest negative impact, I guess is the simplest way to put it. Yeah.

Ulrich Trattner
59:33 - 59:34

Perfect. Thank you very much.

Unknown 3
59:34 - 59:35

Yeah.

Bronwyn Brophy O'Connor
59:35 - 59:39

You're welcome. So, this quarter was strongest on both top and bottom lines.

Operator
59:39 - 59:45

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Bronwyn Brophy O'Connor
59:47 - 59:59

So, I would just like to thank you all for your time this morning. Thank you for your questions, and I wish you all a very nice summer vacation on behalf of myself and Helena Wennerström. Thanks, Amika and Hadoa.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…